Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component

Circ Res. 2004 Jun 25;94(12):1630-7. doi: 10.1161/01.RES.0000130944.49657.b8. Epub 2004 May 6.

Abstract

Angiotensin (Ang) II is now recognized to be a mediator of a wide variety of inflammatory processes. This study investigated renin-angiotensin system (RAS) components and a number of inflammatory mediators in left ventricular biopsies from 2-vessel disease unstable angina (UA) (n=43) and stable angina (SA) (n=15) patients undergoing coronary bypass surgery. Biopsy samples from 6 patients undergoing valve replacement for mitral stenosis served as controls. UA patients were randomly assigned to angiotensin-converting enzyme (ACE)-inhibitor (ramipril), AT1 antagonist (valsartan), or placebo and treated during the 5 days preceding coronary bypass surgery, performed from 6 to 9 days after coronary angiography. During coronary angiography coronary blood flow was measured and samples were obtained from aorta and coronary sinus for determination of Ang I and Ang II gradients. The hearts of UA patients produced Ang II in a greater amount than in SA patients (P<0.01). UA biopsy samples showed numerous DR+ cells, identified as lymphocytes, macrophages, and endothelial cells. Reverse-transcriptase polymerase chain reaction showed overexpression of AGTN, ACE, and AT1-R genes, as well as upregulation of TNF-alpha, IL-6, IFN-gamma, and iNOS genes (P<0.01), with no differences between nonischemic and potentially ischemic areas. AGTN, ACE, and cytokine genes were mainly localized on endothelial cells. Ramipril and valsartan markedly decreased the expression levels of TNF-alpha, IL-6, and iNOS, and, to a lesser extent, of IFN-gamma genes, but did not affect the number of DR+ cells, with no significant difference between the 2 treatments. These results show that locally generated Ang II amplifies the immunomediated inflammatory process of coronary microvessels occurring in unstable angina.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angina Pectoris / complications
  • Angina Pectoris / drug therapy
  • Angina Pectoris / immunology
  • Angina Pectoris / physiopathology
  • Angina Pectoris / surgery
  • Angina, Unstable / complications
  • Angina, Unstable / drug therapy
  • Angina, Unstable / immunology
  • Angina, Unstable / physiopathology*
  • Angina, Unstable / surgery
  • Angiotensin II / biosynthesis
  • Angiotensin II / physiology*
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Chymases
  • Combined Modality Therapy
  • Coronary Angiography
  • Coronary Artery Bypass
  • Coronary Circulation
  • Cytokines / biosynthesis
  • Cytokines / genetics
  • Cytokines / physiology
  • Female
  • Gene Expression Profiling
  • Humans
  • Male
  • Microcirculation / drug effects
  • Middle Aged
  • Mitral Valve Stenosis / physiopathology
  • Myocardium / metabolism
  • Myocardium / pathology
  • Nitric Oxide Synthase / biosynthesis
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase Type II
  • Preoperative Care
  • RNA, Messenger / biosynthesis
  • Ramipril / pharmacology
  • Ramipril / therapeutic use
  • Renin-Angiotensin System / genetics
  • Renin-Angiotensin System / physiology
  • Serine Endopeptidases / biosynthesis
  • Serine Endopeptidases / genetics
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use
  • Valine / analogs & derivatives*
  • Valine / pharmacology
  • Valine / therapeutic use
  • Valsartan
  • Vasculitis / drug therapy
  • Vasculitis / etiology
  • Vasculitis / immunology
  • Vasculitis / physiopathology*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Cytokines
  • RNA, Messenger
  • Tetrazoles
  • Angiotensin II
  • Valsartan
  • NOS2 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Serine Endopeptidases
  • Chymases
  • Valine
  • Ramipril